FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies

• Published in: Frontiers in pharmacology 2023, Vol.14, p.1278056
• Main Authors: Wang, Wanqing, Jiang, Kaipeng, Liu, Xue, Li, Ju, Zhou, Wenshuo, Wang, Chang, Cui, Jiuwei, Liang, Tingting
• Format: Article
• Language: English
• Subjects: drug resistance; Fbxw7; human tumors; targeted therapy; ubiquitin-proteasome system (UPS)
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2023.1278056

Drug therapy, including chemotherapy, targeted therapy, immunotherapy, and endocrine therapy, stands as the foremost therapeutic approach for contemporary human malignancies. However, increasing drug resistance during antineoplastic therapy has become a substantial barrier to favorable outcomes in cancer patients. To enhance the effectiveness of different cancer therapies, an in-depth understanding of the unique mechanisms underlying tumor drug resistance and the subsequent surmounting of antitumor drug resistance is required. Recently, F-box and WD Repeat Domain-containing-7 (FBXW7), a recognized tumor suppressor, has been found to be highly associated with tumor therapy resistance. This review provides a comprehensive summary of the underlying mechanisms through which FBXW7 facilitates the development of drug resistance in cancer. Additionally, this review elucidates the role of FBXW7 in therapeutic resistance of various types of human tumors. The strategies and challenges implicated in overcoming tumor therapy resistance by targeting FBXW7 are also discussed.